capreomycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, produced by Streptomyces strains	3063	11003-38-6

Description:

Molecule

Description

Synonyms:

capreomycin
capastat
capostatin
capreomicin
capromycin
capreomycin sulfate
capreomycine
capreomycine sulfate

Cyclic peptide antibiotic similar to VIOMYCIN. It is produced by Streptomyces capreolus.

Molecular weight: 1321.44
Formula: C50H88N28O15
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA: 378.42
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
1	g	P

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	26.61 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
June 2, 1971	FDA	AKORN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Electrocardiogram QT prolonged	102.93	60.38	31	430	59499	63429062
Drug resistance	101.14	60.38	25	436	22908	63465653
Hepatitis B	92.49	60.38	17	444	3795	63484766

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Electrocardiogram QT prolonged	96.05	43.43	31	431	40921	34915548
Drug resistance	87.63	43.43	26	436	25901	34930568
Hepatotoxicity	49.06	43.43	16	446	21469	34935000
Neuropathy peripheral	48.54	43.43	23	439	83240	34873229

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Electrocardiogram QT prolonged	181.78	42.63	60	928	90326	79653074
Drug resistance	152.52	42.63	44	944	42169	79701231
Hepatitis B	70.02	42.63	17	971	8315	79735085
Neuropathy peripheral	69.14	42.63	34	954	141271	79602129
Optic neuropathy	61.33	42.63	13	975	3471	79739929
Hepatotoxicity	56.82	42.63	22	966	51330	79692070

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J04AB30	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Antibiotics
FDA EPC	N0000175483	Antimycobacterial
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000904	Antibiotics, Antitubercular
MeSH PA	D000995	Antitubercular Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D011500	Protein Synthesis Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Acute tuberculosis	indication	25629007
Pulmonary tuberculosis	indication	154283005	DOID:2957
Hearing loss	contraindication	15188001
Dehydration	contraindication	34095006
Hypokalemia	contraindication	43339004
Neuromuscular block, function	contraindication	55394004
Kidney disease	contraindication	90708001	DOID:557
Disease of liver	contraindication	235856003	DOID:409
Disorder of the 8th Cranial Nerve	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4019652	VUID
N0000178639	NUI
D00135	KEGG_DRUG
4017459	VANDF
4019652	VANDF
C0262964	UMLSCUI
CHEBI:3371	CHEBI
CHEMBL2221250	ChEMBL_ID
D002207	MESH_DESCRIPTOR_UI
DB00314	DRUGBANK_ID
1145	INN_ID
1405-37-4	SECONDARY_CAS_RN
232HYX66HC	UNII
3000502	PUBCHEM_CID
1987	RXNORM
4345	MMSL
d01103	MMSL
002787	NDDF
004901	NDDF
14170004	SNOMEDCT_US
387081001	SNOMEDCT_US
85580008	SNOMEDCT_US
CHEMBL2218913	ChEMBL_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
CAPASTAT SULFATE	HUMAN PRESCRIPTION DRUG LABEL	1	17478-080	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	NDA	23 sections